Home / Health / First Oral Drug Approved for Rare Skin, Muscle Disease
First Oral Drug Approved for Rare Skin, Muscle Disease
28 Aug
Summary
- FDA approved the first oral drug for dermatomyositis.
- Lisraya treats a rare disease affecting skin and muscles.
- The drug showed improvement in skin and muscle symptoms.
The U.S. Food and Drug Administration announced on August 27, 2026, the approval of Lisraya, a groundbreaking oral treatment for dermatomyositis. This marks the first time an oral medication has been sanctioned for this rare condition, which impacts the skin and muscles.
Dermatomyositis causes debilitating symptoms such as painful skin rashes and progressive muscle weakness. Left untreated, it can significantly diminish a patient's quality of life.
Developed by Roivant and Priovant Therapeutics, Lisraya demonstrated efficacy in a late-stage trial, improving both skin and muscle symptoms. Notably, the drug has shown potential to reduce or eliminate the need for steroids, which are commonly prescribed but carry risks of long-term side effects.
This rare disease affects fewer than 5,000 individuals in the United States, making Lisraya a critical new therapeutic option for a patient population with limited treatment choices.
